Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04308759 · ClinicalTrials.gov registry record · Phase 3

An Innovative Conversational Agent (Quitbot) for Smoking Cessation

A Phase 3 study of Cigarette Smoking-Related Carcinoma, sponsored by Fred Hutchinson Cancer Center.

Active
Registry status
Phase 3
Development phase
1,647
Enrollment target
1
Study location

NCT04308759 is a Phase 3 study of Cigarette Smoking-Related Carcinoma that is active but no longer recruiting, run by Fred Hutchinson Cancer Center. The registered enrollment target is 1,647 participants, above the 389-participant average among 21 other Cigarette Smoking-Related Carcinoma trials with a reported enrollment target (323% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04308759, a Phase 3 study of Cigarette Smoking-Related Carcinoma, is active but no longer recruiting, sponsored by Fred Hutchinson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
1,647 participants
Enrollment target
1
Study location

Study Summary

This phase III trial compares two remote digital smoking cessation programs to see how well they work for quitting smoking.

Interventions

  • OTHER Experimental Smoking Cessation Program
  • OTHER Control Smoking Cessation Program

Study Locations (1)

Washington

  • Fred Hutch/University of Washington Cancer Consortium - Seattle

Trial Details

FieldValue
Enrollment Target 1,647 participants
Start Date 2022-07-24
Est. Completion 2026-05-01
Phase Phase 3

Sponsor

Fred Hutchinson Cancer Center

483 total trials

What the Registry Record Tells You About NCT04308759

The ClinicalTrials.gov registry entry for NCT04308759 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,647 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 389-participant average among 21 other Cigarette Smoking-Related Carcinoma trials with a reported enrollment target (323% higher). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cigarette Smoking-Related Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Experimental Smoking Cessation Program is the first listed.

NCT04308759 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT04308759 about?

NCT04308759 is a clinical study titled "An Innovative Conversational Agent (Quitbot) for Smoking Cessation". This phase III trial compares two remote digital smoking cessation programs to see how well they work for quitting smoking.

What is the current status of trial NCT04308759?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,647 participants. The study started on 2022-07-24. Estimated completion is 2026-05-01.

What conditions does trial NCT04308759 study?

This clinical trial studies the following conditions: Cigarette Smoking-Related Carcinoma.

What interventions are being tested in trial NCT04308759?

The interventions under investigation include: Experimental Smoking Cessation Program (OTHER), Control Smoking Cessation Program (OTHER).

Who is sponsoring clinical trial NCT04308759?

This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04308759 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cigarette Smoking-Related Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.